Basilea Pharmaceutica AG (BSLN.SW)
| Previous close | 38.75 |
| Open | 39.00 |
| Bid | 38.50 x 0 |
| Ask | 39.00 x 0 |
| Day's range | 38.55 - 39.00 |
| 52-week range | 32.00 - 49.00 |
| Volume | |
| Avg. volume | 24,791 |
| Market cap | 467.773M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 44.83 |
| EPS (TTM) | 0.86 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Apr 2013 |
| 1y target est | 66.75 |
GlobeNewswireBasilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain can
ZacksBasilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica (BPMUF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s Ch
